Cognition Therapeutics Overview

  • Founded
  • 2007
Founded
  • Status
  • Public
  • Employees
  • 28
Employees
  • Stock Symbol
  • CGTX
Stock Symbol
  • Share Price
  • $2.67
  • (As of Monday Closing)

Cognition Therapeutics General Information

Description

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.

Contact Information

Website
www.cogrx.com
Ownership Status
Publicly Held
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 2500 Westchester Avenue
  • Purchase
  • New York, NY 10577
  • United States
+1 (412) 000-0000

Cognition Therapeutics Timeline

2019202020212022
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Cognition Therapeutics Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.67 $2.51 $2.31 - $13.80 $55.3M 22M 79.8K -$0.54

Cognition Therapeutics Financials Summary

In Thousands,
USD 		TTM 30-Sep-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
Revenue 0 0 0
EBITDA (4,728) (5,990) (3,737)
Net Income (6,245) (7,839) (4,842)
Total Assets 13,389 7,119 7,459
Total Debt 0 12,852 6,901
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Cognition Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cognition Therapeutics‘s full profile, request access.

Request a free trial

Cognition Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion
Price		 % Owned

This information is available in the PitchBook Platform. To explore Cognition Therapeutics‘s full profile, request access.

Request a free trial

Cognition Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of inn
Drug Discovery
New York, NY
28 As of 2021
000.00
0000 0000-00-00
00000000 000.00

000 0000

ipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim v
0000 000000000
Boston, MA
0 As of 0000
000.00
0000000000 0 000.00

00000000

ipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim v
0000 000000000
Clarksville, MD
0 As of 0000
00.000
000000 0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cognition Therapeutics Competitors (47)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
EIP Pharma Venture Capital-Backed Boston, MA 0 000.00 0000000000 0 000.00
000000000000 Venture Capital-Backed Clarksville, MD 0 00.000 000000 0
0000000 Venture Capital-Backed Framingham, MA 00 000.00 00000000000 000.00
0000000 0000000000 Venture Capital-Backed Newton, MA 0 000.00 00000000000 000.00
0000 000000 Formerly VC-backed San Diego, CA 00 00000 00000000 00000
You’re viewing 5 of 47 competitors. Get the full list »

Cognition Therapeutics Patents

  • 82

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 5

    Granted

  • 2

    Pending

  • 000

    Expiring in next 12 mo

Cognition Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3704092-A1 Isoindoline compositions and methods for treating neurodegenerative disease Pending 01-Nov-2017 00000000000
EP-3704092-A4 Isoindoline compositions and methods for treating neurodegenerative disease Pending 01-Nov-2017 00000000000
US-20200338045-A1 Isoindoline compositions and methods for treating neurodegenerative disease Pending 01-Nov-2017 00000000000
CA-3061787-A1 Compositions for treating neurodegenerative diseases Pending 15-May-2017 00000000000
EP-3634394-A1 Compositions for treating neurodegenerative diseases Pending 15-May-2017 C07D295/192
To view Cognition Therapeutics’s complete patent history, request access »

Cognition Therapeutics Executive Team (11)

Name Title Board Seat Contact Info
Lisa Ricciardi Chief Executive Officer & Board Member
James O'Brien Chief Financial Officer, Finance
Susan Catalano Ph.D Chief Scientific Officer & Board Member
Aline Sherwood Associate
Anthony Caggiano MD Chief Medical Officer & Head, Research & Development
You’re viewing 5 of 11 executive team members. Get the full list »

Cognition Therapeutics Board Members (15)

Name Representing Role Since
Aaron Fletcher Ph.D Bios Partners Board Member 000 0000
Brett Monia Ph.D Self Board Member 000 0000
Ellen Richstone Cognition Therapeutics Board Member 000 0000
Jack Khattar Self Chairman & Board Member 000 0000
Lisa Ricciardi Cognition Therapeutics Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 15 board members. Get the full list »

Cognition Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial